Suppression of estrogen-withdrawal headache with extended transdermal contraception.
A randomized clinical trial was conducted with 239 women at nine clinical research sites to compare bleeding profile, headache frequency, and subject satisfaction with the transdermal contraceptive, ORTHO EVRA (norelgestromin/ethinyl estradiol transdermal system) used in an extended regimen (84 days) with a traditional, 28-day cyclic regimen. In a majority of women studied, compared with cyclic use, extended use of transdermal norelgestromin/ethinyl estradiol delayed menses and reduced the total incidence of mean headache days during the hormone-free interval.
LaGuardia
Katherine D
KD
Clinical Affairs, Ortho-McNeil Pharmaceutical, Inc., Raritan, New Jersey 08869, USA. klaguard@ompus.jnj.com
Fisher
Alan C
AC
Bainbridge
James D
JD
LoCoco
John M
JM
Friedman
Andrew J
AJ
D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D005003:Ethisterone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006261:Headache / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D009644:Norgestrel / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010091:Oximes / Q000008:administration & dosage; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000517:prevention & control; D013997:Time Factors
D003692:Delayed-Action Preparations; D004338:Drug Combinations; D010091:Oximes; D009644:Norgestrel; D005003:Ethisterone; C449219:norelgestromin